Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mereo BioPharma (MREO) Non-Current Debt (2020 - 2021)

Mereo BioPharma (MREO) has disclosed Non-Current Debt for 2 consecutive years, with $19.4 million as the latest value for Q4 2021.

  • Quarterly Non-Current Debt fell 9.03% to $19.4 million in Q4 2021 from the year-ago period, while the trailing twelve-month figure was $19.4 million through Dec 2021, down 9.03% year-over-year, with the annual reading at $19.4 million for FY2021, 9.03% down from the prior year.
  • Non-Current Debt for Q4 2021 was $19.4 million at Mereo BioPharma, down from $21.3 million in the prior quarter.
  • The five-year high for Non-Current Debt was $21.3 million in Q4 2020, with the low at $19.4 million in Q4 2021.